Compare Noble Corporation plc (NE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Zoetis Inc — how do they compare? Noble Corporation plc trades at $42.5 (market cap $6.73B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 4.5× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.74%). Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 26 Days and Zoetis Inc for 70 Days on average.
| NE | ZTS | |
|---|---|---|
Market Cap | $6.73B | $30.20B |
Volume | 1,027,635 | 6,175,327 |
Sector | Energy | Health |
52-Week High | $54.37 | $147.53 |
52-Week Low | $26.70 | $69.09 |
Typical Hold Time | 26 Days | 70 Days |
Enterprise Value | $8.16B | $37.76B |
Dividend Yield | 4.74% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $42.56, up 3.88% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported $3.29B revenue for 2025 with a 4.88% net income margin, though recent quarterly earnings have been inconsistent with two misses and one beat. Analyst sentiment is divided with a $52 consensus price target representing 22% upside potential, but ongoing legal investigations create uncertainty.
The stock presents a moderate opportunity with significant analyst upside potential, supported by recent contract wins including the long-term Ghana drilling agreement. However, risks include inconsistent earnings performance, declining profitability margins from 2025 to 2026, and multiple ongoing legal investigations that could impact investor confidence and stock performance in the near term.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
